Kineta Inc.

Kineta Inc.: Kineta (Private) expertise in innate immunity and immunology. Wholly owned preclinical human anti-VISTA antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. VISTA is the most highly expressed checkpoint in hard to treat tumors. $360M+ deal with Genentech for KCP506 non-opioid for chronic pain, a first in class a9/a10 Nicotinic Acetylcholine Receptor (nAChR) antagonist - initiated Ph1 4Q2020. LHF-535 for the treatment of Lassa Fever wholly funded by Wellcome Trust (priority review voucher upon approval, Ph2/3 start in 2021).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Anti-infectives, Antivirals, Autoimmune, Dermatology, Immuno-Oncology, Immunotherapy, Infectious Disease, Ophthalmology, Pain
Finance
Pre-Revenues
Industry
Biotechnology
Investement Strategy
Under the Radar
Listing
Private
Market Cap
Private
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
219 Terry Ave N.
Suite 300
Seattle, WA 98109
United States

Company Participants at Spring Private Company Showcase

Shawn Iadonato, PhD
Kineta Inc., CEO/Co-Founder
Dr. Shawn Iadonato serves as Kineta’s Chief Executive Officer. He has nearly twenty years of experience leading startup biotech companies. Dr. Iadonato is a co-founder of Kineta and initially served as Chief Scientific Officer. Under his leadership at Kineta, the company established a proprietary screening platform for identifying small molecule innate immune modulators and has advanced novel drug programs in immuno-oncology, neuroscience and biodefense. The company also established strategic partnerships with Pfizer, Genentech and the Wellcome Trust. Prior to founding Kineta, Dr. Iadonato co-founded and served as CSO of Illumigen Biosciences, Inc. At Illumigen Biosciences, he pioneered a patented drug discovery platform which relied upon recruitment and screening of healthy populations and elucidation of their shared “wellness” genes. Dr. Iadonato also led the successful discovery and preclinical development of Illumigen’s anti-hepatitis C drug, which ultimately led to the sale of the company to Cubist Pharmaceuticals (now part of Merck & Co.) in 2007. Before Illumigen, Dr. Iadonato managed the Human Genome Center at the University of Washington. He is co-inventor on more than 35 U.S. patents or patent applications. He is Principal Investigator or co-Investigator on numerous government grants and contracts. Dr. Iadonato received a Ph.D. in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.

Upcoming Company Event Participation